<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gestational hypertension</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gestational hypertension</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gestational hypertension</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lissa M Melvin, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Edmund F Funai, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Gestational hypertension and preeclampsia (including chronic hypertension with superimposed preeclampsia, eclampsia, and HELLP syndrome [hemolysis, elevated liver enzymes, and low platelets]) are hypertensive disorders induced by pregnancy that resolve postpartum. Because of this and other similarities (gestational hypertension often progresses to preeclampsia), some do not consider them independent disorders. On the other hand, studies of risk factors note that although their risk factors are similar, there are differences in the magnitude of associations with each disorder. For example, primiparity, multiple gestation, and diabetes mellitus are stronger risk factors for preeclampsia than for gestational hypertension [<a href="#rid1">1,2</a>]. Prognosis is also different: the recurrence rate for gestational hypertension is several-fold higher than that for preeclampsia (&gt;20 percent versus approximately 5 percent for preeclampsia at term) [<a href="#rid3">3,4</a>]. Physiologic and histologic differences also exist between the two disorders. Total blood and plasma volumes are significantly higher in patients with gestational hypertension (3139 mL/m<sup>2</sup> and 2132 mL/m<sup>2</sup>, respectively) than in those with preeclampsia (mean 2660 mL/m<sup>2</sup> and 1790 mL/m<sup>2</sup>, respectively) [<a href="#rid5">5</a>], Doppler measures of arterial and venous hemodynamics and vascular endothelial function are normal in patients with gestational hypertension and abnormal in those with preeclampsia [<a href="#rid6">6,7</a>], and levels of microparticles associated with endothelial cell damage are significantly lower in patients with gestational hypertension than in those with preeclampsia [<a href="#rid8">8</a>]. Histologic signs of placental ischemia are less prominent in gestational hypertension than in preeclampsia [<a href="#rid9">9</a>].</p><p>This topic will discuss gestational hypertension. Preeclampsia, superimposed preeclampsia, eclampsia, and HELLP syndrome are reviewed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6825.html" rel="external">"Preeclampsia: Antepartum management and timing of delivery"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/116432.html" rel="external">"Chronic hypertension in pregnancy: Prenatal and postpartum care", section on 'Patients with superimposed preeclampsia'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1662.html" rel="external">"Eclampsia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6778.html" rel="external">"HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets)"</a>.)</p><p></p><p class="headingAnchor" id="H1618026459"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>In a population-based prospective cohort study beginning in early pregnancy (median gestational duration 14 weeks), gestational hypertension developed in 2 to 17 percent of the cohort and preeclampsia developed in 2 to 5 percent [<a href="#rid10">10</a>]. Participants with obesity had the highest prevalence of gestational hypertension.</p><p class="headingAnchor" id="H1189790606"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Risk factors are similar to those for preeclampsia (see  <a class="medical medical_review" href="/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis", section on 'Risk factors'</a>). However, epidemiologic studies report differences in the magnitude of the associations with each disorder [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL FINDINGS AND DIAGNOSIS</span><span class="headingEndMark"> — </span>Gestational hypertension should be suspected in a pregnant patient with <strong>all</strong> of the following [<a href="#rid11">11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>New onset of hypertension</strong> (systolic pressure ≥140 mmHg and/or diastolic pressure ≥90 mmHg) at ≥20 weeks of gestation. </p><p></p><p class="bulletIndent1">The blood pressure elevation generally should be documented on at least two occasions at least four hours apart. However, it is neither necessary nor desirable to wait hours before confirming and treating severe blood pressure elevations (systolic pressure ≥160 mmHg and/or diastolic pressure ≥110 mmHg). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normal urine protein excretion for pregnancy </strong>– Normal protein excretion in pregnancy is &lt;300 mg per 24-hour urine collection (or this amount extrapolated from a timed collection), or protein-to-creatinine ratio &lt;0.3, or urine dipstick reading &lt;2+ (if other quantitative methods are not available).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Absence of the signs and symptoms of end-organ dysfunction</strong> associated with preeclampsia with severe features, which are described in the table  (<a class="graphic graphic_table graphicRef76975" href="/d/graphic/76975.html" rel="external">table 1</a>).</p><p></p><p>The diagnosis of gestational hypertension is confirmed postpartum if the patient does not subsequently develop proteinuria or new signs of end-organ dysfunction (which are criteria for preeclampsia), and the hypertension does not persist ≥12 weeks postpartum (which suggests chronic hypertension).</p><p class="headingAnchor" id="H4"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H4292909044"><span class="h2">Goals</span><span class="headingEndMark"> — </span>The main goals in the initial evaluation of pregnant patients with newly developed hypertension are to:</p><p class="bulletIndent1"><span class="glyph">●</span>Confirm elevated blood pressure (exclude white coat hypertension)</p><p class="bulletIndent1"><span class="glyph">●</span>Distinguish gestational hypertension from preeclampsia, which can have a different course and short-term prognosis</p><p></p><p class="headingAnchor" id="H1504473114"><span class="h2">Confirm hypertension</span><span class="headingEndMark"> — </span>Systolic pressure ≥140 mmHg and/or diastolic pressure ≥90 mmHg on at least two occasions at least four hours apart confirms hypertension. As discussed above, it is neither necessary nor desirable to wait hours before confirming and treating severe blood pressure elevation (systolic pressure ≥160 mmHg and/or diastolic pressure ≥110 mmHg). (See <a class="local">'Clinical findings and diagnosis'</a> above and <a class="local">'Management: blood pressures ≥160/110 mmHg'</a> below.) </p><p>Accurate blood pressure assessment requires proper technique (see  <a class="medical medical_review" href="/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients", section on 'Technique for accurate measurement of blood pressure'</a>) and excluding white coat hypertension (also called isolated clinic or office hypertension). The latter can be excluded by repeating the blood pressure measurement when the patient is relaxed. Results of home blood pressure monitoring can be useful to establish the patient's blood pressure profile [<a href="#rid12">12</a>]. Approximately 30 percent of pregnant participants in a trial of self-blood pressure monitoring had discordancy between the home and office readings, most of which were attributed to white coat hypertension [<a href="#rid13">13,14</a>]. (See  <a class="medical medical_review" href="/d/html/3820.html" rel="external">"Out-of-office blood pressure measurement: Ambulatory and self-measured blood pressure monitoring"</a>.)</p><p class="headingAnchor" id="H2743212564"><span class="h2">Ask about symptoms</span><span class="headingEndMark"> — </span>Gestational hypertension is asymptomatic. Preeclampsia without severe features is also asymptomatic, whereas patients with severe features may have new-onset cerebral or visual symptoms (eg, photopsia, scotomata, cortical blindness, retinal vasospasm); severe headache or a headache that persists and progresses despite analgesic therapy with <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> and not accounted for by alternative diagnoses; severe persistent right upper quadrant or epigastric pain unresponsive to medication and not accounted for by an alternative diagnosis; and/or dyspnea due to pulmonary edema. (See  <a class="medical medical_review" href="/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Measure protein excretion, platelet count, and chemistries</span><span class="headingEndMark"> — </span>Absence of proteinuria is a key criterion that distinguishes gestational hypertension from preeclampsia. In gestational hypertension, protein excretion should be &lt;300 mg in a 24-hour urine collection, or the protein-to-creatinine ratio should be &lt;0.3 in a random urine specimen, or the urine dipstick should be &lt;2+ if other quantitative methods are not available. A negative to trace urine dipstick does not definitively exclude significant proteinuria since false-negative results occur with low specific gravity (&lt;1.010), high salt concentration, highly acidic urine, or with nonalbuminic proteinuria. A positive urine dipstick value, especially if only +1, also requires confirmation since false positives occur. (See  <a class="medical medical_review" href="/d/html/4808.html" rel="external">"Proteinuria in pregnancy: Diagnosis, differential diagnosis, and management of nephrotic syndrome"</a>.)</p><p>Even after a normal 24-hour urine collection or protein-to-creatinine ratio, it can be difficult to exclude preeclampsia conclusively because 10 percent of pregnant patients with other clinical and/or histologic manifestations of preeclampsia have no proteinuria and 20 percent of those with eclampsia do not have significant proteinuria prior to seizing [<a href="#rid15">15</a>]. </p><p>Laboratory evaluation (platelet count, creatinine, alanine transaminase, aspartate transaminase) helps to determine whether end-organ damage has occurred (findings are listed in the table  (<a class="graphic graphic_table graphicRef76975" href="/d/graphic/76975.html" rel="external">table 1</a>)), which can happen with preeclampsia but not with gestational hypertension. (See  <a class="medical medical_review" href="/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H876357307"><span class="h2">Rule out other causes of hypertension</span><span class="headingEndMark"> — </span>Previously unrecognized chronic hypertension is a possibility when prepregnancy blood pressures are not available for comparison with blood pressures during pregnancy. Some pregnant people may have undiagnosed prepregnancy hypertension. When such individuals present for prenatal care, they may have normal blood pressures because of normal early pregnancy physiology. Development of isolated hypertension later in pregnancy may reflect return to their baseline blood pressure level rather than gestational hypertension. Similarly, if they present late in gestation for prenatal care and have isolated hypertension, it is difficult to determine whether this reflects chronic hypertension or gestational hypertension. </p><p>Secondary causes of hypertension are listed and described in the table  (<a class="graphic graphic_table graphicRef56130" href="/d/graphic/56130.html" rel="external">table 2</a>) and discussed separately (see  <a class="medical medical_review" href="/d/html/3862.html" rel="external">"Evaluation of secondary hypertension"</a>). In addition, acute hypertension can be caused by use of drugs that can produce a hyperadrenergic state, such as cocaine, amphetamine(s), and phencyclidine. A standardized interview to screen for misuse of substances can be performed; some examples are provided in the table  (<a class="graphic graphic_table graphicRef128222" href="/d/graphic/128222.html" rel="external">table 3</a>). The Society for Maternal-Fetal Medicine suggests considering drug testing in patients with acute clinical complications such as unexplained severe hypertension [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/126975.html" rel="external">"Hypertensive disorders in pregnancy: Approach to differential diagnosis"</a> and  <a class="medical medical_review" href="/d/html/13846.html" rel="external">"Testing for drugs of abuse (DOAs)"</a>.)</p><p class="headingAnchor" id="H14926620"><span class="h1">RISK OF PROGRESSION TO PREECLAMPSIA</span><span class="headingEndMark"> — </span>Ten to 50 percent of patients diagnosed with gestational hypertension go on to develop preeclampsia in the next one to five weeks [<a href="#rid17">17,18</a>]. It is unclear whether gestational hypertension and preeclampsia are independent diseases with a similar phenotype (hypertension) or if gestational hypertension is an early mild stage of preeclampsia.</p><p class="headingAnchor" id="H3486191382"><span class="h2">Predictive factors</span><span class="headingEndMark"> — </span>Patients who progress to preeclampsia have characteristics different from those who continue to have nonproteinuric nonsevere hypertension. Clinical characteristics at presentation of gestational hypertension that predict an increased risk for progression to preeclampsia include gestational age &lt;34 weeks at diagnosis (sensitivity 85 percent, specificity 60 percent) or mean systolic blood pressure &gt;135 mmHg on 24-hour blood pressure monitoring (sensitivity 61 percent, specificity 76 percent) [<a href="#rid19">19</a>]. Placental growth factor (PlGF)-based tests are sometimes used to rule in or rule out preeclampsia in patients suspected of the disorder. (See  <a class="medical medical_review" href="/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis", section on 'Role of measurement of angiogenic markers'</a>.)</p><p class="headingAnchor" id="H1634365973"><span class="h1">MANAGEMENT: BLOOD PRESSURES ≥160/110 MMHG</span><span class="headingEndMark"> — </span>Patients who develop severe gestational hypertension have rates of pregnancy complications comparable to those of patients with preeclampsia with severe features; thus, the two groups are managed similarly [<a href="#rid11">11</a>].</p><p>Severe hypertension should be confirmed with a repeat measurement within five minutes and, if confirmed, should be treated expeditiously in the hospital  (<a class="graphic graphic_algorithm graphicRef134292" href="/d/graphic/134292.html" rel="external">algorithm 1</a>). Delivery is generally indicated, regardless of gestational age, given the high risk of serious maternal morbidity. However, expectant management in a tertiary care setting or in consultation with a maternal-fetal medicine specialist is an option for selected patients remote from term (&lt;34 weeks of gestation) in whom blood pressure can be controlled. Management of these patients is reviewed separately. (See  <a class="medical medical_review" href="/d/html/6825.html" rel="external">"Preeclampsia: Antepartum management and timing of delivery", section on 'Preeclampsia with features of severe disease'</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">MANAGEMENT: BLOOD PRESSURES &lt;160/110 MMHG</span></p><p class="headingAnchor" id="H905188814"><span class="h2">Site of care</span><span class="headingEndMark"> — </span>Patients with gestational hypertension without severe blood pressure elevation can be managed safely as outpatients if they are able to comply with weekly or twice weekly office visits [<a href="#rid12">12,20</a>].</p><p class="headingAnchor" id="H1542014928"><span class="h2">Patient education and counseling</span><span class="headingEndMark"> — </span>Patient education and counseling are important components of management since these patients are at increased risk of developing preeclampsia. We instruct them to promptly report any symptoms suggestive of preeclampsia (headache, visual changes, epigastric or right upper quadrant pain). We also review signs suggestive of possible fetal compromise, such as decreased fetal movement and vaginal bleeding, and signs of preterm labor.</p><p class="headingAnchor" id="H14927476"><span class="h2">Level of physical activity</span><span class="headingEndMark"> — </span>Patients may maintain most of their normal physical activities. Bedrest at home or in the hospital does not prevent progression to preeclampsia or improve maternal or fetal outcome compared with usual activity, but reduces the risk of developing severe hypertension (odds ratio 0.47, 95% CI 0.26-0.83) [<a href="#rid21">21,22</a>]. The decision to advise reduced physical activity should be individualized, taking into consideration the patient's blood pressures, comorbidities, and psychosocial factors.</p><p>We advise against strength training and pure isometric exercise, such as weightlifting, as these activities can acutely raise blood pressure to severe levels. Aerobic exercise can cause a modest rise in systolic pressure, usually with no change or a slight reduction in diastolic pressure. In the absence of information about patients' blood pressure responses to their usual aerobic exercise activities, we advise against aerobic exercise.</p><p>Whether and how many hours patients continue to work outside the home depend on multiple factors, particularly their blood pressure at work. These decisions should be made on a case-by-case basis. (See  <a class="medical medical_review" href="/d/html/439.html" rel="external">"Working during pregnancy", section on 'Work characteristics'</a>.)</p><p class="headingAnchor" id="H14928751"><span class="h2">Maternal blood pressure and laboratory monitoring</span></p><p class="bulletIndent1"><span class="glyph">●</span>We obtain in-office blood pressure measurements once or twice weekly when the patient comes in for a prenatal visit. Ideally, this is supplemented with home blood pressure monitoring to determine the patient's average and peak blood pressures serially during usual activity, and exclude the effects of white coat hypertension [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We assess the following laboratory tests weekly:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Urine protein-to-creatinine ratio</p><p class="bulletIndent2"><span class="glyph">•</span>Platelet count</p><p class="bulletIndent2"><span class="glyph">•</span>Serum creatinine</p><p class="bulletIndent2"><span class="glyph">•</span>Alanine transaminase, aspartate transaminase</p><p></p><p class="bulletIndent1">Proteinuria, thrombocytopenia, renal insufficiency, or elevated transaminases change the diagnosis to preeclampsia, which affects management and prognosis. (See  <a class="medical medical_review" href="/d/html/6825.html" rel="external">"Preeclampsia: Antepartum management and timing of delivery"</a> and  <a class="medical medical_review" href="/d/html/139247.html" rel="external">"Preeclampsia: Intrapartum and postpartum management and long-term prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H2932604845"><span class="h2">Role of antihypertensive therapy</span><span class="headingEndMark"> — </span>We hospitalize and prescribe antihypertensive drugs for patients with severe hypertension, frequent blood pressures approaching the severe range, or with preexisting end-organ dysfunction (eg, kidney or heart disease) that may be worsened by hypertension. In rare complex patients with labile pressures that are occasionally approaching the severe range, we offer antihypertensive therapy with the goal of maintaining blood pressures in the range of 130 to 140/85 to 90 mmHg. Choice of drug(s), dosing, and target pressure are described in detail separately. (See  <a class="medical medical_review" href="/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients", section on 'When to initiate antihypertensive therapy in pregnancy'</a>.)</p><p>The American College of Obstetricians and Gynecologists (ACOG) suggests pharmacotherapy of gestational hypertension when systolic pressures are ≥160 mmHg or diastolic pressures are ≥110 mmHg, or both [<a href="#rid11">11</a>]. By comparison, the National Institute for Health and Care Excellence suggests offering pharmacotherapy to patients with gestational hypertension if their blood pressure remains above 140/90 mmHg [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H3189079609"><span class="h2">Fetal monitoring</span><span class="headingEndMark"> — </span>The need for, type, and frequency of fetal assessment in patients with nonsevere gestational hypertension is controversial [<a href="#rid24">24</a>]. There is no evidence from large randomized trials that any routine surveillance method results in a decreased risk of fetal death or neonatal morbidity in these patients. Nevertheless, antepartum fetal monitoring of pregnancies deemed to be at increased risk of adverse fetal outcome is a routine obstetric practice in the United States.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>NST, BPP</strong> – We monitor fetal well-being by a weekly biophysical profile (BPP) or nonstress test (NST) plus assessment of amniotic fluid volume, increasing the frequency to twice weekly in patients with comorbidities. We also ask them to monitor fetal movement daily and call if it decreases. (See  <a class="medical medical_review" href="/d/html/457.html" rel="external">"Overview of antepartum fetal assessment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Estimated fetal weight</strong> – We also obtain a sonographic estimation of fetal weight. If the initial examination is normal, we repeat the ultrasound examination every three to four weeks as hypertension of any etiology may be associated with placental insufficiency, which can lead to impaired fetal growth [<a href="#rid25">25,26</a>]. If growth restriction with or without oligohydramnios is present, management is the same as in any pregnancy with this finding and reviewed separately. (See  <a class="medical medical_review" href="/d/html/139556.html" rel="external">"Fetal growth restriction: Pregnancy management and outcome"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of Doppler</strong> – We reserve use Doppler velocimetry for monitoring fetuses with growth restriction, but some non-US guidelines include various Doppler parameters for diagnosis of growth restriction as well  (<a class="graphic graphic_table graphicRef139438" href="/d/graphic/139438.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/139556.html" rel="external">"Fetal growth restriction: Pregnancy management and outcome"</a> and  <a class="medical medical_review" href="/d/html/6752.html" rel="external">"Fetal growth restriction: Screening and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H16"><span class="h2">Antenatal corticosteroids</span><span class="headingEndMark"> — </span>If the clinician believes that an individual patient is at increased risk for delivery within seven days and before 34 weeks of gestation (eg, coexistent pregnancy complications, development of preeclampsia), then a course of antenatal corticosteroids (ACS) should be administered. ACS is not routinely administered to patients with nonsevere gestational hypertension because preterm birth &lt;34 weeks is uncommon. A review of pregnancy outcomes in patients with nonsevere gestational hypertension found that delivery before 34 weeks occurred in only 1 to 5 percent of cases [<a href="#rid24">24</a>].</p><p>Use of ACS at late-preterm gestational ages is more controversial. (See  <a class="medical medical_review" href="/d/html/6796.html" rel="external">"Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery"</a>.)</p><p class="headingAnchor" id="H3479634696"><span class="h2">No role for low-dose aspirin</span><span class="headingEndMark"> — </span>Whether low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> prevents progression of gestational hypertension to preeclampsia is unclear. We do <strong>not</strong> begin aspirin for prevention of preeclampsia after 20 weeks of gestation and therefore do not prescribe it for patients with gestational hypertension.</p><p>Meta-analyses have found that beginning low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> in the second trimester to pregnant people at average or high risk of developing preeclampsia is associated with a modest reduction in preeclampsia and its sequelae (growth restriction, preterm birth) [<a href="#rid27">27</a>]. Most participants in these trials began low-dose aspirin before 20 weeks of gestation and the trials had a wide variety of inclusion and exclusion criteria, with some including and others excluding individuals with gestational hypertension. A detailed discussion regarding use of low-dose aspirin for preeclampsia prophylaxis is available separately. (See  <a class="medical medical_review" href="/d/html/6817.html" rel="external">"Preeclampsia: Prevention", section on 'Low-dose aspirin'</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Timing of delivery</span><span class="headingEndMark"> — </span>We plan for a term rather than preterm delivery, in general agreement with guidelines from multiple major societies [<a href="#rid28">28</a>]. We individualize timing at term based on the blood pressure level, comorbidities, and other risk factors for adverse pregnancy outcome. Our approach tries to balance the fetal benefits of expectant management (ie, further growth and maturation) with the maternal and fetal risks of expectant management (eg, progression to preeclampsia or severe gestational hypertension and possible sequelae, including stillbirth or asphyxia), which may be avoided by early delivery.</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with gestational hypertension who have only a few blood pressures ≥140/90 mmHg but &lt;160/110 mmHg and otherwise uncomplicated pregnancies (no comorbidities or other risk factors for adverse outcome), we plan delivery for 38+0 to 39+0 weeks, or at diagnosis if diagnosed later. We believe maternal morbidity is unlikely to increase from only occasional episodes of nonsevere blood pressure elevation, whereas the extra one to two weeks of expectant management is likely to reduce neonatal morbidity. Our approach is supported by findings of a retrospective cohort study in patients with gestational hypertension from the Consortium on Safe Labor in which induction between 38 and 39 weeks of gestation achieved the optimal balance of low maternal and low neonatal morbidity/mortality [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with gestational hypertension who have frequent blood pressures ≥140/90 mmHg but &lt;160/110 mmHg, comorbidities, or other risk factors for adverse outcome, we plan delivery for 37+0 weeks or at diagnosis if diagnosed later. Delivery at 37 weeks rather than later in this more complicated patient population is supported by the HYPITAT-I trial, which randomly assigned patients at 36+0 to 41+0 weeks with gestational hypertension or mild preeclampsia to immediate delivery or expectant management and found immediate induction reduced the composite risk of poor maternal outcome (new-onset severe preeclampsia, HELLP syndrome, eclampsia, pulmonary edema, placental abruption: 31 versus 44 percent, relative risk 0.71, 95% CI 0.59-0.86), without significantly increasing neonatal morbidity at or near term [<a href="#rid30">30</a>]. HYPITAT-II, which was performed in patients at 34+0 to 36+6 weeks of gestation, also found immediate delivery reduced maternal morbidity, but noted that the maternal benefit of preterm delivery was small in contrast to the significant increase in neonatal morbidity with delivery before 37 weeks [<a href="#rid31">31</a>].</p><p></p><p>Our approach is similar to that of a consensus opinion of a workshop held by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Society for Maternal-Fetal Medicine that suggested delivery at 37+0 to 38+6 weeks for all patients with any degree of gestational hypertension because of the risk of progression to preeclampsia [<a href="#rid32">32</a>]. It differs from an ACOG practice bulletin, based largely on expert opinion, that suggests delivery rather than expectant management for all patients with uncomplicated gestational hypertension at ≥37+0 weeks [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H1034777174"><span class="h2">Route of birth</span><span class="headingEndMark"> — </span>Most patients give birth vaginally. Cesarean birth is performed for standard obstetric indications.</p><p class="headingAnchor" id="H231261449"><span class="h2">Intrapartum management</span><span class="headingEndMark"> — </span>Intrapartum care is routine, with the following points:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitor for development of severe hypertension or preeclampsia</strong> – During labor, we monitor patients for development of proteinuria, worsening hypertension, and symptoms of severe disease since preeclampsia can manifest intrapartum. Intrapartum management of preeclampsia is reviewed separately. (See  <a class="medical medical_review" href="/d/html/139247.html" rel="external">"Preeclampsia: Intrapartum and postpartum management and long-term prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9585" href="/d/drug information/9585.html" rel="external">Magnesium sulfate</a> – We do not administer magnesium sulfate seizure prophylaxis unless the patient develops severe hypertension or preeclampsia with severe features  (<a class="graphic graphic_table graphicRef76975" href="/d/graphic/76975.html" rel="external">table 1</a>) [<a href="#rid11">11</a>]. </p><p></p><p class="bulletIndent1">Magnesium sulphate is administered for fetal neuroprotection in pregnancies less than 32 weeks. (See  <a class="medical medical_review" href="/d/html/4481.html" rel="external">"Neuroprotective effects of in utero exposure to magnesium sulfate"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anesthesia</strong> – Intrapartum anesthesia for patients with gestational hypertension and preeclampsia without severe features is managed as it would be for patients without these disorders, recognizing that severity may increase at any time. (See  <a class="medical medical_review" href="/d/html/94369.html" rel="external">"Anesthesia for the patient with preeclampsia"</a>.)</p><p></p><p class="headingAnchor" id="H3368469375"><span class="h2">Postpartum care</span><span class="headingEndMark"> — </span>Postpartum care is routine. Patients with excessive uterine bleeding due to atony should not receive <a class="drug drug_general" data-topicid="9637" href="/d/drug information/9637.html" rel="external">methylergonovine</a> as it exacerbates hypertension. (See  <a class="medical medical_review" href="/d/html/6714.html" rel="external">"Postpartum hemorrhage: Medical and minimally invasive management", section on 'Manage atony'</a>.)</p><p>For most patients, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> and/or nonsteroidal anti-inflammatory agents provide safe and effective analgesia. (See  <a class="medical medical_review" href="/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients", section on 'Analgesia'</a>.)</p><p>Blood pressure should be followed closely after discharge since blood pressure peaks three to six days postpartum when most patients are at home. Patients should be advised to seek medical attention if they develop severe headaches or if blood pressure increases to severe levels. ACOG suggests daily blood pressure evaluation for 72 hours postpartum and again around 7 to 10 days postpartum, or earlier in patients with symptoms [<a href="#rid33">33,34</a>]. Another approach is to ensure measurement at least once during postpartum days 3 to 5 [<a href="#rid35">35</a>]. Adjunctive home blood pressure monitoring is useful for daily monitoring. Blood pressure returns to the prepregnancy baseline in most patients within two to six weeks. (See <a class="local">'Resolution of gestational hypertension'</a> below.)</p><p class="headingAnchor" id="H19"><span class="h1">MATERNAL PROGNOSIS</span></p><p class="headingAnchor" id="H42894607"><span class="h2">Resolution of gestational hypertension</span><span class="headingEndMark"> — </span>Approximately 50 percent of patients will have blood pressures &lt;140/90 mmHg without antihypertensive medication by two weeks postpartum, 80 percent by six weeks [<a href="#rid36">36</a>], and all by 12 weeks (unless they had unrecognized preexisting chronic hypertension).</p><p class="headingAnchor" id="H42894614"><span class="h2">Recurrence risk</span><span class="headingEndMark"> — </span>In a meta-analysis of individual patient data from almost 24,000 patients with gestational hypertension who became pregnant again, 22 percent developed hypertension in a subsequent pregnancy: gestational hypertension 15 percent, preeclampsia 7 percent [<a href="#rid37">37</a>]. </p><p>Given these data, other data that individuals with a strong risk factor or several moderate risk factors for preeclampsia benefit from low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> therapy during pregnancy, and the minimal risk of harm, we offer patients with a history of gestational hypertension low-dose aspirin in future pregnancies. The evidence for this recommendation is available separately. (See  <a class="medical medical_review" href="/d/html/6817.html" rel="external">"Preeclampsia: Prevention", section on 'Candidates'</a>.)</p><p class="headingAnchor" id="H42894621"><span class="h2">Long-term prognosis</span><span class="headingEndMark"> — </span>Gestational hypertension is associated with development of hypertension later in life, and also with development of diseases related to hypertension (cardiovascular disease, hyperlipidemia, chronic kidney disease, diabetes mellitus) [<a href="#rid38">38-46</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>A prospective study of over 15,000 patients with a first singleton birth observed that those with gestational hypertension in three consecutive pregnancies had significantly higher blood pressure later in life than patients who remained normotensive (systolic pressure 27 mmHg higher, diastolic pressure 12 mmHg higher) [<a href="#rid40">40</a>]. They also had more unfavorable lipid and glycemic profiles, but these differences appeared to be due to higher body mass index at follow-up in patients with a history of hypertension in pregnancy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study, patients with both gestational hypertension and gestational diabetes were at particularly high risk for future diabetes (hazard ratio [HR] 36.9, 95% CI 26.0-52.3), hypertension (HR 5.7, 95% CI 4.9-6.7), and cardiovascular disease/mortality (HR 2.4, 95% CI 1.6-3.5) compared with patients who had neither disorder, but no information on maternal weight was available [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a third study, gestational hypertension was associated with a twofold increased risk of cardiovascular disease during 14 years of postpartum follow-up, and the risk increased in those with small for gestational age (SGA) infants and/or preterm birth [<a href="#rid45">45</a>].</p><p></p><p>Gestational hypertension and preeclampsia appear to have similar long-term cardiovascular risks, including chronic hypertension. Many long-term outcome studies evaluate outcomes among females with a history of "pregnancy-induced hypertension," given some uncertainty in the distinction between gestational hypertension and preeclampsia. The long-term risks of preeclampsia are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/139247.html" rel="external">"Preeclampsia: Intrapartum and postpartum management and long-term prognosis", section on 'Long-term maternal risks of pregnancy-associated hypertension'</a>.)</p><p>Clinical monitoring, risk factor evaluation, and early intervention might benefit patients with a history of hypertension of any etiology in pregnancy. (See  <a class="medical medical_review" href="/d/html/7573.html" rel="external">"Overview of primary prevention of cardiovascular disease"</a> and  <a class="medical medical_review" href="/d/html/1546.html" rel="external">"Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach"</a>.)</p><p class="headingAnchor" id="H14927093"><span class="h1">PERINATAL OUTCOME</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonsevere hypertension</strong> – Pregnancy outcomes of patients with nonsevere gestational hypertension are generally favorable [<a href="#rid18">18,24,48-52</a>]. Most studies report that the mean birth weight and rates of growth restriction, preterm birth, abruption, and perinatal death are similar to those in the general obstetric population. However, one population-based cohort study reported that the risk of delivering a small for gestational age (SGA) newborn at term increased by 2 percent for each mmHg rise in diastolic blood pressure from early to late pregnancy, even in the absence of overt hypertension [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe hypertension</strong> – Pregnancies associated with severe gestational hypertension appear to be at increased risk of maternal and perinatal morbidity [<a href="#rid2">2,18,24,48-51</a>]. These pregnancies have rates of preterm birth, SGA, and placental abruption significantly higher than the rates in the general obstetric population, and similar rates to those reported for patients with severe features of preeclampsia.</p><p></p><p class="bulletIndent1">In a study that compared selected outcomes in patients with severe preeclampsia (n = 45), severe gestational hypertension (n = 24), and mild gestational hypertension or normotension (n = 467), the preterm birth rates &lt;35 weeks were 36, 25, and 8 percent, respectively, and SGA rates were 11, 21, and 7 percent, respectively [<a href="#rid49">49</a>]. The small number of patients with severe gestational hypertension or severe preeclampsia limits the generalizability of these results.</p><p></p><p class="headingAnchor" id="H3815421633"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109729.html" rel="external">"Society guideline links: Hypertensive disorders of pregnancy"</a>.)</p><p class="headingAnchor" id="H7861657"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/16893.html" rel="external">"Patient education: High blood pressure and pregnancy (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations and diagnosis</strong> – Gestational hypertension should be suspected in a pregnant patient with <strong>all</strong> of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>New-onset hypertension (systolic pressure ≥140 mmHg and/or diastolic pressure ≥90 mmHg) at ≥20 weeks of gestation</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Normal urine protein excretion for pregnancy<strong> </strong>(&lt;300 mg per 24-hour urine collection, or protein-to-creatinine ratio &lt;0.3, or urine dipstick reading &lt;2+)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Absent signs and symptoms of end-organ dysfunction associated with preeclampsia with severe features  (<a class="graphic graphic_table graphicRef76975" href="/d/graphic/76975.html" rel="external">table 1</a>)</p><p></p><p class="bulletIndent1">The diagnosis is confirmed postpartum if the patient does not subsequently develop criteria for preeclampsia and the hypertension does not persist ≥12 weeks postpartum (which suggests chronic hypertension). (See <a class="local">'Clinical findings and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation </strong>– The main goal is to confirm elevated blood pressure (exclude white coat hypertension) and distinguish gestational hypertension from preeclampsia by documenting absence of the symptoms and laboratory abnormalities listed in the table  (<a class="graphic graphic_table graphicRef79977" href="/d/graphic/79977.html" rel="external">table 5</a>). (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Systolic pressure ≥160 mmHg and/or diastolic pressure ≥110 mmHg</strong> –<strong> </strong>Management is the same as that for preeclampsia with severe features. Severe hypertension should be treated urgently  (<a class="graphic graphic_algorithm graphicRef134292" href="/d/graphic/134292.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/6825.html" rel="external">"Preeclampsia: Antepartum management and timing of delivery", section on 'Preeclampsia with features of severe disease'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Systolic pressure &lt;160 mmHg and diastolic pressure &lt;110 mmHg</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Ten to 50 percent of these patients will go on to develop preeclampsia in the next one to five weeks, thus they require close outpatient monitoring and counseling about signs of symptoms of the disease. (See <a class="local">'Risk of progression to preeclampsia'</a> above and <a class="local">'Patient education and counseling'</a> above and <a class="local">'Site of care'</a> above and <a class="local">'Level of physical activity'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We measure blood pressure once or twice weekly and measure urine protein, platelet count, and liver transaminases weekly. (See <a class="local">'Maternal blood pressure and laboratory monitoring'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We monitor fetal well-being weekly with a biophysical profile (BPP) or nonstress test (NST) plus assessment of amniotic fluid volume, increasing the frequency to twice weekly in patients with comorbidities. We also obtain an initial sonographic estimation of fetal weight. If this examination is normal, we repeat the ultrasound examination every three to four weeks. (See <a class="local">'Fetal monitoring'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Antenatal corticosteroids (ACS) are administered for standard indications. (See  <a class="medical medical_review" href="/d/html/6796.html" rel="external">"Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of delivery</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Systolic pressure ≥160 mmHg and/or diastolic pressure ≥110 mmHg </strong>–<strong> </strong>Management is the same as that for preeclampsia with severe features. Expeditious delivery is generally indicated, regardless of gestational age, given the high risk of serious maternal morbidity. However, expectant management in a tertiary care setting or in consultation with a maternal-fetal medicine specialist is an option for selected patients &lt;34 weeks of gestation in whom blood pressure can be controlled. Management of preeclampsia with severe features is reviewed separately. (See  <a class="medical medical_review" href="/d/html/6825.html" rel="external">"Preeclampsia: Antepartum management and timing of delivery", section on 'Preeclampsia with features of severe disease'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Frequent blood pressures ≥140/90 mmHg but &lt;160/110 mmHg, comorbidities, or other risk factors for adverse outcome</strong> –<strong> </strong>We suggest delivery at 37+0 weeks of gestation, or at diagnosis if diagnosed later (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Timing of delivery'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Uncomplicated pregnancies (no comorbidities or other risk factors for adverse outcome) with most blood pressures &lt;140/90 mmHg but intermittent values of ≥140/90 mmHg but &lt;160/110 mmHg</strong> – We suggest delivery at 38+0 to 39+0 weeks, or at diagnosis if diagnosed later (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Timing of delivery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcome</strong> – Pregnancy outcomes of patients with nonsevere gestational hypertension are generally favorable. Severe gestational hypertension is associated with increased risks of maternal and perinatal morbidity (preterm birth, small for gestational age [SGA] neonate, placental abruption). Later in life, these mothers are at increased risk of developing chronic hypertension and related disorders (eg, cardiovascular disease, hyperlipidemia, chronic kidney disease, diabetes mellitus). (See <a class="local">'Perinatal outcome'</a> above and <a class="local">'Long-term prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrence risk </strong>– Hypertension recurs in approximately 22 percent of subsequent pregnancies (gestational hypertension 15 percent, preeclampsia 7 percent) (see <a class="local">'Recurrence risk'</a> above). Therefore, we treat patients with low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> in future pregnancies. The evidence for this recommendation is available separately. (See  <a class="medical medical_review" href="/d/html/6817.html" rel="external">"Preeclampsia: Prevention", section on 'Low-dose aspirin'</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ros HS, Cnattingius S, Lipworth L. Comparison of risk factors for preeclampsia and gestational hypertension in a population-based cohort study. Am J Epidemiol 1998; 147:1062.</a></li><li><a class="nounderline abstract_t">Villar J, Carroli G, Wojdyla D, et al. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions? Am J Obstet Gynecol 2006; 194:921.</a></li><li><a class="nounderline abstract_t">Hjartardottir S, Leifsson BG, Geirsson RT, Steinthorsdottir V. Recurrence of hypertensive disorder in second pregnancy. Am J Obstet Gynecol 2006; 194:916.</a></li><li><a class="nounderline abstract_t">Brown MA, Mackenzie C, Dunsmuir W, et al. Can we predict recurrence of pre-eclampsia or gestational hypertension? BJOG 2007; 114:984.</a></li><li><a class="nounderline abstract_t">Silver HM, Seebeck M, Carlson R. Comparison of total blood volume in normal, preeclamptic, and nonproteinuric gestational hypertensive pregnancy by simultaneous measurement of red blood cell and plasma volumes. Am J Obstet Gynecol 1998; 179:87.</a></li><li><a class="nounderline abstract_t">Noori M, Donald AE, Angelakopoulou A, et al. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 2010; 122:478.</a></li><li><a class="nounderline abstract_t">Gyselaers W, Staelens A, Mesens T, et al. Maternal venous Doppler characteristics are abnormal in pre-eclampsia but not in gestational hypertension. Ultrasound Obstet Gynecol 2015; 45:421.</a></li><li><a class="nounderline abstract_t">González-Quintero VH, Smarkusky LP, Jiménez JJ, et al. Elevated plasma endothelial microparticles: preeclampsia versus gestational hypertension. Am J Obstet Gynecol 2004; 191:1418.</a></li><li><a class="nounderline abstract_t">Maloney KF, Heller D, Baergen RN. Types of maternal hypertensive disease and their association with pathologic lesions and clinical factors. Fetal Pediatr Pathol 2012; 31:319.</a></li><li><a class="nounderline abstract_t">Gaillard R, Steegers EA, Hofman A, Jaddoe VW. Associations of maternal obesity with blood pressure and the risks of gestational hypertensive disorders. The Generation R Study. J Hypertens 2011; 29:937.</a></li><li><a class="nounderline abstract_t">Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol 2020; 135:e237. Reaffirmed 2023.</a></li><li><a class="nounderline abstract_t">Denolle T, Weber JL, Calvez C, et al. Diagnosis of white coat hypertension in pregnant women with teletransmitted home blood pressure. Hypertens Pregnancy 2008; 27:305.</a></li><li><a class="nounderline abstract_t">Chappell LC, Tucker KL, Galal U, et al. Effect of Self-monitoring of Blood Pressure on Blood Pressure Control in Pregnant Individuals With Chronic or Gestational Hypertension: The BUMP 2 Randomized Clinical Trial. JAMA 2022; 327:1666.</a></li><li><a class="nounderline abstract_t">Tucker KL, Mort S, Yu LM, et al. Effect of Self-monitoring of Blood Pressure on Diagnosis of Hypertension During Higher-Risk Pregnancy: The BUMP 1 Randomized Clinical Trial. JAMA 2022; 327:1656.</a></li><li><a class="nounderline abstract_t">Sibai BM. Eclampsia. VI. Maternal-perinatal outcome in 254 consecutive cases. Am J Obstet Gynecol 1990; 163:1049.</a></li><li><a class="nounderline abstract_t">Ecker J, Abuhamad A, Hill W, et al. Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine. Am J Obstet Gynecol 2019; 221:B5.</a></li><li><a class="nounderline abstract_t">Saudan P, Brown MA, Buddle ML, Jones M. Does gestational hypertension become pre-eclampsia? Br J Obstet Gynaecol 1998; 105:1177.</a></li><li><a class="nounderline abstract_t">Barton JR, O'brien JM, Bergauer NK, et al. Mild gestational hypertension remote from term: progression and outcome. Am J Obstet Gynecol 2001; 184:979.</a></li><li><a class="nounderline abstract_t">Melamed N, Ray JG, Hladunewich M, et al. Gestational hypertension and preeclampsia: are they the same disease? J Obstet Gynaecol Can 2014; 36:642.</a></li><li><a class="nounderline abstract_t">Cartwright W, Dalton KJ, Swindells H, et al. Objective measurement of anxiety in hypertensive pregnant women managed in hospital and in the community. Br J Obstet Gynaecol 1992; 99:182.</a></li><li><a class="nounderline abstract_t">Crowther CA, Bouwmeester AM, Ashurst HM. Does admission to hospital for bed rest prevent disease progression or improve fetal outcome in pregnancy complicated by non-proteinuric hypertension? Br J Obstet Gynaecol 1992; 99:13.</a></li><li><a class="nounderline abstract_t">Meher S, Abalos E, Carroli G. Bed rest with or without hospitalisation for hypertension during pregnancy. Cochrane Database Syst Rev 2005; :CD003514.</a></li><li class="breakAll">NICE guideline. Hypertension in pregnancy: diagnosis and management. June 2019. www.nice.org.uk/guidance/ng133 (Accessed on May 25, 2022).</li><li><a class="nounderline abstract_t">Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003; 102:181.</a></li><li><a class="nounderline abstract_t">Corrêa RR, Gilio DB, Cavellani CL, et al. Placental morphometrical and histopathology changes in the different clinical presentations of hypertensive syndromes in pregnancy. Arch Gynecol Obstet 2008; 277:201.</a></li><li><a class="nounderline abstract_t">Magee LA, von Dadelszen P, Bohun CM, et al. Serious perinatal complications of non-proteinuric hypertension: an international, multicentre, retrospective cohort study. J Obstet Gynaecol Can 2003; 25:372.</a></li><li><a class="nounderline abstract_t">Henderson JT, Whitlock EP, O'Conner E, et al. Low-Dose Aspirin for the Prevention of Morbidity and Mortality From Preeclampsia: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US) 2014.</a></li><li><a class="nounderline abstract_t">Gillon TE, Pels A, von Dadelszen P, et al. Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines. PLoS One 2014; 9:e113715.</a></li><li><a class="nounderline abstract_t">Cruz MO, Gao W, Hibbard JU. What is the optimal time for delivery in women with gestational hypertension? Am J Obstet Gynecol 2012; 207:214.e1.</a></li><li><a class="nounderline abstract_t">Koopmans CM, Bijlenga D, Groen H, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet 2009; 374:979.</a></li><li><a class="nounderline abstract_t">Broekhuijsen K, van Baaren GJ, van Pampus MG, et al. Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): an open-label, randomised controlled trial. Lancet 2015; 385:2492.</a></li><li><a class="nounderline abstract_t">Spong CY, Mercer BM, D'alton M, et al. Timing of indicated late-preterm and early-term birth. Obstet Gynecol 2011; 118:323.</a></li><li><a class="nounderline abstract_t">ACOG Committee Opinion No. 736: Optimizing Postpartum Care. Obstet Gynecol 2018; 131:e140. Reaffirmed 2021.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013; 122:1122.</a></li><li><a class="nounderline abstract_t">Wu P, Green M, Myers JE. Hypertensive disorders of pregnancy. BMJ 2023; 381:e071653.</a></li><li><a class="nounderline abstract_t">Palatnik A, Mukhtarova N, Hetzel SJ, Hoppe KK. Blood pressure changes in gestational hypertension, preeclampsia, and chronic hypertension from preconception to 42-day postpartum. Pregnancy Hypertens 2023; 31:25.</a></li><li><a class="nounderline abstract_t">van Oostwaard MF, Langenveld J, Schuit E, et al. Recurrence of hypertensive disorders of pregnancy: an individual patient data metaanalysis. Am J Obstet Gynecol 2015; 212:624.e1.</a></li><li><a class="nounderline abstract_t">Reiter L, Brown MA, Whitworth JA. Hypertension in pregnancy: the incidence of underlying renal disease and essential hypertension. Am J Kidney Dis 1994; 24:883.</a></li><li><a class="nounderline abstract_t">Wilson BJ, Watson MS, Prescott GJ, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ 2003; 326:845.</a></li><li><a class="nounderline abstract_t">Magnussen EB, Vatten LJ, Smith GD, Romundstad PR. Hypertensive disorders in pregnancy and subsequently measured cardiovascular risk factors. Obstet Gynecol 2009; 114:961.</a></li><li><a class="nounderline abstract_t">Robbins CL, Dietz PM, Bombard J, Valderrama AL. Gestational hypertension: a neglected cardiovascular disease risk marker. Am J Obstet Gynecol 2011; 204:336.e1.</a></li><li><a class="nounderline abstract_t">Männistö T, Mendola P, Vääräsmäki M, et al. Elevated blood pressure in pregnancy and subsequent chronic disease risk. Circulation 2013; 127:681.</a></li><li><a class="nounderline abstract_t">Behrens I, Basit S, Lykke JA, et al. Association Between Hypertensive Disorders of Pregnancy and Later Risk of Cardiomyopathy. JAMA 2016; 315:1026.</a></li><li><a class="nounderline abstract_t">Tooher J, Thornton C, Makris A, et al. All Hypertensive Disorders of Pregnancy Increase the Risk of Future Cardiovascular Disease. Hypertension 2017; 70:798.</a></li><li><a class="nounderline abstract_t">Riise HKR, Sulo G, Tell GS, et al. Association Between Gestational Hypertension and Risk of Cardiovascular Disease Among 617 589 Norwegian Women. J Am Heart Assoc 2018; 7.</a></li><li><a class="nounderline abstract_t">Barrett PM, McCarthy FP, Evans M, et al. Hypertensive disorders of pregnancy and the risk of chronic kidney disease: A Swedish registry-based cohort study. PLoS Med 2020; 17:e1003255.</a></li><li><a class="nounderline abstract_t">Pace R, Brazeau AS, Meltzer S, et al. Conjoint Associations of Gestational Diabetes and Hypertension With Diabetes, Hypertension, and Cardiovascular Disease in Parents: A Retrospective Cohort Study. Am J Epidemiol 2017; 186:1115.</a></li><li><a class="nounderline abstract_t">Hauth JC, Ewell MG, Levine RJ, et al. Pregnancy outcomes in healthy nulliparas who developed hypertension. Calcium for Preeclampsia Prevention Study Group. Obstet Gynecol 2000; 95:24.</a></li><li><a class="nounderline abstract_t">Buchbinder A, Sibai BM, Caritis S, et al. Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. Am J Obstet Gynecol 2002; 186:66.</a></li><li><a class="nounderline abstract_t">Hnat MD, Sibai BM, Caritis S, et al. Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparas. Am J Obstet Gynecol 2002; 186:422.</a></li><li><a class="nounderline abstract_t">Knuist M, Bonsel GJ, Zondervan HA, Treffers PE. Intensification of fetal and maternal surveillance in pregnant women with hypertensive disorders. Int J Gynaecol Obstet 1998; 61:127.</a></li><li><a class="nounderline abstract_t">Cruz MO, Gao W, Hibbard JU. Obstetrical and perinatal outcomes among women with gestational hypertension, mild preeclampsia, and mild chronic hypertension. Am J Obstet Gynecol 2011; 205:260.e1.</a></li><li><a class="nounderline abstract_t">Wikström AK, Gunnarsdottir J, Nelander M, et al. Prehypertension in Pregnancy and Risks of Small for Gestational Age Infant and Stillbirth. Hypertension 2016; 67:640.</a></li></ol></div><div id="topicVersionRevision">Topic 6805 Version 73.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9620050" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Comparison of risk factors for preeclampsia and gestational hypertension in a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16580277" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16580276" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Recurrence of hypertensive disorder in second pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17573736" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Can we predict recurrence of pre-eclampsia or gestational hypertension?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9704770" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comparison of total blood volume in normal, preeclamptic, and nonproteinuric gestational hypertensive pregnancy by simultaneous measurement of red blood cell and plasma volumes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20644016" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24890401" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Maternal venous Doppler characteristics are abnormal in pre-eclampsia but not in gestational hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15507976" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Elevated plasma endothelial microparticles: preeclampsia versus gestational hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22432966" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Types of maternal hypertensive disease and their association with pathologic lesions and clinical factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21430559" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Associations of maternal obesity with blood pressure and the risks of gestational hypertensive disorders. The Generation R Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32443079" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18696359" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Diagnosis of white coat hypertension in pregnant women with teletransmitted home blood pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35503345" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effect of Self-monitoring of Blood Pressure on Blood Pressure Control in Pregnant Individuals With Chronic or Gestational Hypertension: The BUMP 2 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35503346" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effect of Self-monitoring of Blood Pressure on Diagnosis of Hypertension During Higher-Risk Pregnancy: The BUMP 1 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2403130" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Eclampsia. VI. Maternal-perinatal outcome in 254 consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30928567" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9853766" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Does gestational hypertension become pre-eclampsia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11303208" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Mild gestational hypertension remote from term: progression and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25184984" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Gestational hypertension and preeclampsia: are they the same disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1606113" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Objective measurement of anxiety in hypertensive pregnant women managed in hospital and in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1547164" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Does admission to hospital for bed rest prevent disease progression or improve fetal outcome in pregnancy complicated by non-proteinuric hypertension?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16235323" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Bed rest with or without hospitalisation for hypertension during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16235323" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Bed rest with or without hospitalisation for hypertension during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12850627" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Diagnosis and management of gestational hypertension and preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17786461" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Placental morphometrical and histopathology changes in the different clinical presentations of hypertensive syndromes in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12738978" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Serious perinatal complications of non-proteinuric hypertension: an international, multicentre, retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24783270" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Low-Dose Aspirin for the Prevention of Morbidity and Mortality From Preeclampsia: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25436639" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22831812" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : What is the optimal time for delivery in women with gestational hypertension?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19656558" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25817374" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): an open-label, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21775849" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Timing of indicated late-preterm and early-term birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29683911" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : ACOG Committee Opinion No. 736: Optimizing Postpartum Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24150027" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’Task Force on Hypertension in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37391211" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hypertensive disorders of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36512857" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Blood pressure changes in gestational hypertension, preeclampsia, and chronic hypertension from preconception to 42-day postpartum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25582098" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Recurrence of hypertensive disorders of pregnancy: an individual patient data metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7985664" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Hypertension in pregnancy: the incidence of underlying renal disease and essential hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12702615" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20168095" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Hypertensive disorders in pregnancy and subsequently measured cardiovascular risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21183153" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Gestational hypertension: a neglected cardiovascular disease risk marker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23401113" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Elevated blood pressure in pregnancy and subsequent chronic disease risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26954411" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Association Between Hypertensive Disorders of Pregnancy and Later Risk of Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28893895" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : All Hypertensive Disorders of Pregnancy Increase the Risk of Future Cardiovascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29755034" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Association Between Gestational Hypertension and Risk of Cardiovascular Disease Among 617 589 Norwegian Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32797043" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Hypertensive disorders of pregnancy and the risk of chronic kidney disease: A Swedish registry-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29149255" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Conjoint Associations of Gestational Diabetes and Hypertension With Diabetes, Hypertension, and Cardiovascular Disease in Parents: A Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10636496" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Pregnancy outcomes in healthy nulliparas who developed hypertension. Calcium for Preeclampsia Prevention Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11810087" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11904601" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9639216" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Intensification of fetal and maternal surveillance in pregnant women with hypertensive disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22071056" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Obstetrical and perinatal outcomes among women with gestational hypertension, mild preeclampsia, and mild chronic hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26831196" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Prehypertension in Pregnancy and Risks of Small for Gestational Age Infant and Stillbirth.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
